Pixium Vision (PXMVF) Stock Price, News & Analysis

Company Overview

Pixium Vision is a clinical-stage medical device company headquartered in Paris, France, that specializes in the development of bionic vision systems for patients with severe vision loss. Founded in 2006, Pixium Vision focuses on harnessing neuro-technologies to restore useful vision by converting images captured by a miniature camera into electrical impulses that stimulate the retina. The company’s technology platform is designed to address retinal degenerative conditions such as retinitis pigmentosa and geographic atrophy due to age-related macular degeneration.

The flagship product under development is the PRIMA system, a wireless sub-retinal implant composed of photovoltaic micro-chips that transform pulsed light into electronic stimulation of the remaining retinal cells. In parallel, Pixium Vision is advancing the IRIS® II epiretinal prosthesis for patients with profound vision loss. Both systems are undergoing early-phase clinical trials in Europe and the United States, where the company collaborates with leading ophthalmology centers to assess safety, tolerability and preliminary efficacy.

Pixium Vision serves a global patient population through a network of clinical partners and regulatory approvals that enable trials in France, Germany and the United States. The company maintains R&D activities at its Paris headquarters and supports U.S. operations from its subsidiary in Silicon Valley. Research collaborations with academic institutions and specialized hospitals further bolster the company’s efforts to refine implant design and improve visual outcomes.

Guided by a management team with expertise in biomedical engineering, ophthalmology and neuroscience, Pixium Vision continues to build its product pipeline while advancing its clinical programs. Its long-term vision is to deliver commercially viable bionic vision solutions that enhance independence and quality of life for patients affected by retinal diseases.

Key Stats

• Today's Range: C$75.00 to C$75.00
• 50-Day Range: C$75.00 to C$75.00
• 52-Week Range: C$0.03 to C$0.03
• Volume: N/A
• Average Volume: 8,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXMVF Stock Analysis - Frequently Asked Questions

How have PXMVF shares performed this year?

Pixium Vision's stock was trading at C$1.50 at the start of the year. Since then, PXMVF stock has increased by 4,900.0% and is now trading at C$75.00.

When did Pixium Vision's stock split?

Pixium Vision shares reverse split before market open on Thursday, September 21st 2023.The 1-50 reverse split was announced on Thursday, September 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Pixium Vision?

Shares of PXMVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PXMVF
• CIK: N/A
• Web: www.pixium-vision.com
• Phone: 33 1 76 21 47 68
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A